^
Association details:
| Biomarker: | EML4-ALK L1196M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Qi Xinke (iruplinalkib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
Published date:
04/10/2023
Excerpt:
The activity of iruplinalkib on cell viability was next examined in several cell lines…in Ba/F3 cells expressing EML4-ALKL1196M or EML4-ALKC1156Y fusion proteins, iruplinalkib was slightly more potent. Cell growth IC50 values for iruplinalkib were 9.5 and 9 nM, compared with 19.5 and 14 nM, respectively, for brigatinib....As a novel ALK/ROS1 inhibitor with high activity and selectivity, iruplinalkib exhibited strong antitumor activity in vitro and in vivo, and also had antitumor effects in crizotinib-resistant models. This study provided a partial molecular biological basis for iruplinalkib in the treatment of crizotinib-resistant or non-resistant ALK-positive NSCLC...
DOI:
10.1007/s10637-023-01350-x
